Enoxaparin Sodium Injection
Product Images NDC 63323-566

Product Visual Gallery

This gallery contains 46 technical images submitted to the FDA as part of the official labeling for Enoxaparin Sodium (NDC 63323-566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Enoxa-img-01.jpg (Enoxa Img 01)

An instructional diagram illustrating how to use a syringe for subcutaneous injection. The image shows two hands holding the syringe, with a double-headed arrow indicating movement or adjustment along the syringe barrel.*

FDA Label Image

Enoxa-img-02.jpg (Enoxa Img 02)

An instructional illustration labeled 'Figure B' showing a hand removing or handling a cap from a vial or syringe, indicated by an arrow pointing downward.*

FDA Label Image

Enoxa-img-03.jpg (Enoxa Img 03)

An instructional line drawing labeled 'Figure C' showing a hand removing or placing a small cap or tab on a vial or syringe device, depicted by curved and rectangular shapes, likely part of procedural steps for medication preparation or injection.*

FDA Label Image

Enoxa-img-04.jpg (Enoxa Img 04)

An instructional illustration labeled 'Figure D' showing a hand holding a syringe with the thumb pushing a plunger, indicating the injection technique or step in administering Enoxaparin Sodium by subcutaneous injection.*

FDA Label Image

Enoxa-img-05.jpg (Enoxa Img 05)

An instructional diagram labeled 'Figure E' showing a hand disposing of a used syringe into a container marked with a biohazard symbol, indicating proper safe disposal of injection materials.*

FDA Label Image

Enoxa-struc-01.jpg (Enoxa Struc 01)

Chemical structure of Enoxaparin Sodium, showing its polysaccharide backbone with repeating disaccharide units, including sodium carboxylate and sulfate groups as specified in the diagram.*

FDA Label Image

Enoxa-struc-02.jpg (Enoxa Struc 02)

Chemical structure of Enoxaparin Sodium, showing the molecular arrangement including multiple ring structures, hydroxyl groups, sodium carboxylate, and sulfate functional groups.*

FDA Label Image

Enoxa-img-06.jpg (Enoxa Img 06)

A forest plot chart showing relative risk comparisons between Enoxaparin Sodium and UFH across various patient subgroups. The chart includes patient numbers, relative risk with confidence intervals, and percentage risk outcomes for each treatment, highlighting the reduction in risk associated with Enoxaparin Sodium in different conditions such as sex, age, infarct location, diabetes status, prior myocardial infarction, fibrinolytic agent use, time to treatment, and PCI within 30 days.*

FDA Label Image

Enoxa-img-07.jpg (Enoxa Img 07)

A survival analysis chart showing the hazard distribution function over time (up to 30 days) for death or myocardial reinfarction comparing Enoxaparin and UFH (unfractionated heparin). The graph includes a main plot and a smaller inset plot showing data at one year, with corresponding log-rank test p-values indicating statistical comparisons. Number at risk for both Enoxaparin and UFH groups is listed below the x-axis.*

FDA Label Image

Enoxa-img-08.jpg (Enoxa Img 08)

FDA Label Image

Enoxa-img-09.jpg (Enoxa Img 09)

An instructional illustration showing the Enoxaparin Sodium injection syringe before and after use. The 'Before Use' image highlights the plunger rod, needle, and needle cap on the syringe. The 'After Use' image shows the syringe with the plunger rod fully pressed and a protective sleeve covering the needle.*

FDA Label Image

Enoxa-img-10.jpg (Enoxa Img 10)

An instructional diagram labeled Figure A showing the components for administering Enoxaparin Sodium injection. It includes a prefilled syringe of Enoxaparin Sodium, a sharps disposal container, one cotton ball or gauze, one alcohol wipe, and one small adhesive bandage.*

FDA Label Image

Enoxa-img-11.jpg (Enoxa Img 11)

An instructional illustration showing a pair of hands preparing an injection device. One hand holds the syringe with a visible dose scale, while the other hand peels back a protective covering from the syringe or needle area, suggesting preparation for use.*

FDA Label Image

Enoxa-img-12.jpg (Enoxa Img 12)

An instructional diagram labeled Figure C showing a syringe with a plunger, barrel, and needle cover. The syringe includes a marked area indicating where the expiration date is located on the barrel. The image is related to Enoxaparin Sodium injection, used for subcutaneous administration.*

FDA Label Image

Enoxa-img-13.jpg (Enoxa Img 13)

An instructional diagram labeled Figure D showing a syringe filled with a clear liquid, indicating the presence of the liquid medication inside the syringe barrel. The syringe is depicted with measurement markings and a plunger.*

FDA Label Image

Enoxa-img-14.jpg (Enoxa Img 14)

An illustration labeled 'Figure E' showing a front view of a human torso with two shaded rectangular areas on the lower abdomen, likely indicating injection sites for subcutaneous administration.*

FDA Label Image

Enoxa-img-15.jpg (Enoxa Img 15)

An instructional illustration showing a person applying a small adhesive patch or dressing to the abdomen area, likely demonstrating correct site preparation or application technique for a subcutaneous injection.*

FDA Label Image

Enoxa-img-16.jpg (Enoxa Img 16)

An instructional illustration showing two hands holding a syringe, with one hand removing a protective cap from the needle. A double-headed arrow indicates the motion of pulling the cap off the syringe needle. The image likely relates to preparing an injection for administration.*

FDA Label Image

Enoxa-img-17.jpg (Enoxa Img 17)

An instructional illustration showing a hand holding a syringe with an arrow pointing downward, indicating to set or adjust the dose on the syringe. The image is labeled 'Figure H' and includes the text 'Set your dose.' This diagram is related to dosing with a syringe injection.*

FDA Label Image

Enoxa-img-18.jpg (Enoxa Img 18)

A black-and-white instructional illustration showing a hand pinching a fold of skin, likely demonstrating the technique for subcutaneous injection site preparation.*

FDA Label Image

Enoxa-img-19.jpg (Enoxa Img 19)

Instructional diagram showing the subcutaneous injection technique. It depicts a hand holding a syringe and injecting at a 90-degree angle into the skin, demonstrating proper administration of Enoxaparin Sodium injection subcutaneously.*

FDA Label Image

Enoxa-img-20.jpg (Enoxa Img 20)

An instructional illustration showing a person administering a subcutaneous injection into the skin of the thigh. The image depicts a hand holding a syringe, inserting the needle at an angle into the skin, with an arrow indicating the direction of the injection.*

FDA Label Image

Enoxa-img-21.jpg (Enoxa Img 21)

An instructional illustration showing a hand administering a subcutaneous injection to the abdomen. A syringe with the plunger partially depressed is positioned near the skin, with an arrow indicating the direction of injection.*

FDA Label Image

Enoxa-img-22.jpg (Enoxa Img 22)

An instructional illustration showing a hand holding a syringe labeled with a "Protective Sleeve." An arrow and the word "CLICK" indicate pushing the plunger or a component until an audible click is felt. This diagram likely demonstrates part of the preparation or activation of the Enoxaparin Sodium injection device.*

FDA Label Image

Enoxa-img-23.jpg (Enoxa Img 23)

Illustration showing a hand holding a prefilled syringe labeled Enoxaparin Sodium with a needle cap. The syringe is being positioned above a sharps disposal container for safe disposal of the needle.*

FDA Label Image

Enoxa-label-01.jpg (Enoxa Label 01)

Packaging label for Enoxaparin Sodium Injection, USP 30 mg per 0.3 mL, single dose syringes with automatic safety device for subcutaneous injection. Sterile, contains 10 syringes of 0.3 mL each. Labeler is Fresenius Kabi USA, LLC. Includes dosage form, strength, NDC 63323-559-93, and usage instructions with safety illustrations.*

FDA Label Image

Enoxa-label-02.jpg (Enoxa Label 02)

Label for Enoxaparin Sodium Injection, USP 30 mg per 0.3 mL in a single dose syringe with automatic safety device. It is for subcutaneous injection and comes in a 0.3 mL syringe. The product is manufactured for Fresenius Kabi USA, LLC, with storage recommended at 20° to 25°C (68° to 77°F). The label includes Rx only designation and safety warnings.*

FDA Label Image

Enoxa-label-03.jpg (Enoxa Label 03)

Label for Enoxaparin Sodium Injection, USP 30 mg per 0.3 mL, a subcutaneous injection manufactured for Fresenius Kabi USA, LLC. The label includes the NDC 63323-559-21 and states the product is made in India. A barcode and a numeric code are visible on the right side of the label.*

FDA Label Image

Enoxa-label-04.jpg (Enoxa Label 04)

Packaging label for Enoxaparin Sodium Injection, USP 40 mg per 0.4 mL, a subcutaneous injection in single-dose syringes with an automatic safety device. The label indicates the product is sterile and contains 10 syringes of 0.4 mL each. The manufacturer is Fresenius Kabi USA, LLC. The label also includes directions for use with illustrated steps for operating the safety device.*

FDA Label Image

Enoxa-label-05.jpg (Enoxa Label 05)

Label for Enoxaparin Sodium Injection, USP 40 mg per 0.4 mL in a single dose syringe with automatic safety device. The label indicates subcutaneous injection use with a 0.4 mL syringe. Manufactured for Fresenius Kabi USA, LLC, made in India, with storage instructions and a safety warning to keep out of reach of children.*

FDA Label Image

Enoxa-label-06.jpg (Enoxa Label 06)

Enoxaparin Sodium Injection, USP 40 mg per 0.4 mL subcutaneous injection label showing NDC 63323-564-21. Manufactured for Fresenius Kabi USA, LLC and made in India. The label includes Rx only designation, lot and expiration placeholders, and a QR code for tracking.*

FDA Label Image

Enoxa-label-07.jpg (Enoxa Label 07)

Packaging label for Enoxaparin Sodium Injection, USP 60 mg per 0.6 mL in single dose syringes with automatic safety device, intended for subcutaneous injection. The label indicates a sterile product by Fresenius Kabi USA, LLC and includes dosage information, barcodes, and illustrated directions for use and safe disposal of the syringe.*

FDA Label Image

Enoxa-label-08.jpg (Enoxa Label 08)

Label for Enoxaparin Sodium Injection, USP, 60 mg per 0.6 mL syringe. Single-dose syringe with automatic safety device for subcutaneous injection. Manufactured for Fresenius Kabi USA, LLC, with storage instructions at 20° to 25°C. Includes barcode and lot/control number areas, and directions to lift to peel the label.*

FDA Label Image

Enoxa-label-09.jpg (Enoxa Label 09)

Label for Enoxaparin Sodium Injection, USP 60 mg per 0.6 mL, intended for subcutaneous injection. The product is manufactured for Fresenius Kabi and made in India. The label includes an NDC number (63323-566-21), lot and expiration placeholders, and a barcode.*

FDA Label Image

Enoxa-label-10.jpg (Enoxa Label 10)

Packaging label for Enoxaparin Sodium Injection, USP 80 mg per 0.8 mL single dose syringes with automatic safety device for subcutaneous injection. The label indicates the product is sterile and contains 10 syringes of 0.8 mL each. The labeler is Fresenius Kabi USA, LLC. Instructions for syringe use and safety are also shown on the packaging.*

FDA Label Image

Enoxa-label-11.jpg (Enoxa Label 11)

Enoxaparin Sodium Injection, USP 80 mg per 0.8 mL, single dose syringe with automatic safety device for subcutaneous injection. The label includes dosage and administration instructions, storage conditions, and a warning. Manufactured by Fresenius Kabi USA, LLC, made in India. The label also features barcodes and a peel-back section.*

FDA Label Image

Enoxa-label-12.jpg (Enoxa Label 12)

Label for Enoxaparin Sodium Injection, USP 80 mg per 0.8 mL, a subcutaneous injection manufactured by Fresenius Kabi. The label includes the NDC 63323-584-21, indicates 'Rx only,' and notes the product is made in India. It also features a QR code and barcode on the right side.*

FDA Label Image

Enoxa-label-13.jpg (Enoxa Label 13)

Packaging label for Enoxaparin Sodium Injection, USP, 100 mg per mL, in single-dose syringes with automatic safety device for subcutaneous injection. The label indicates 10 syringes of 1 mL each, marked sterile, with storage instructions and manufacturer Fresenius Kabi USA, LLC. The label includes dosage and administration information, warnings, and syringe use directions.*

FDA Label Image

Enoxa-label-14.jpg (Enoxa Label 14)

This is a drug information panel for Enoxaparin Sodium Injection, USP 100 mg/mL in a single-dose 1 mL syringe with an automatic safety device, for subcutaneous injection. It includes dosage instructions referencing the package insert, storage conditions at 20° to 25°C, a warning to keep out of reach of children, and manufacturer details for Fresenius Kabi USA, LLC, made in India. A barcode and peel tab are also visible.*

FDA Label Image

Enoxa-label-15.jpg (Enoxa Label 15)

Label for Enoxaparin Sodium Injection, USP 100 mg per mL, for subcutaneous injection. Manufactured for Fresenius Kabi USA, LLC, made in India. The label includes NDC 63323-586-21 and a 2D barcode on the right side, along with lot and expiration details not fully visible.*

FDA Label Image

Enoxa-label-16.jpg (Enoxa Label 16)

Label for Enoxaparin Sodium Injection, USP, 120 mg per 0.8 mL single dose syringes with automatic safety device for subcutaneous injection. The label indicates a package of 10 syringes, sterile, manufactured by Fresenius Kabi USA, LLC. Directions for use with illustrations of syringe handling and safety device activation are included. The design features a purple and white color scheme with the Fresenius Kabi logo.*

FDA Label Image

Enoxa-label-17.jpg (Enoxa Label 17)

Drug Facts panel for Enoxaparin Sodium Injection, USP 120 mg per 0.8 mL in a single-dose syringe with an automatic safety device. It specifies subcutaneous injection use, dosage and administration details including concentration graduation, storage instructions at 20° to 25°C, a warning to keep out of reach of children, and manufacturing details by Fresenius Kabi USA, LLC, noting the product is made in India.*

FDA Label Image

Enoxa-label-18.jpg (Enoxa Label 18)

Label for Enoxaparin Sodium Injection, USP 120 mg per 0.8 mL for subcutaneous injection. The label displays the NDC 63323-655-21 and indicates the product is manufactured by Fresenius Kabi in India. It includes a QR code and space for lot and expiration details.*

FDA Label Image

Enoxa-label-19.jpg (Enoxa Label 19)

Packaging label for Enoxaparin Sodium Injection, USP 150 mg per mL, presented in single-dose syringes with automatic safety device. Designed for subcutaneous injection, sterile, containing 10 x 1 mL syringes. Label includes dosage information, warnings, directions for use with illustrations, and is manufactured for Fresenius Kabi USA, LLC. The label features a blue grid design and prominent dosage display.*

FDA Label Image

Enoxa-label-20.jpg (Enoxa Label 20)

Enoxaparin Sodium Injection, USP 150 mg/mL single dose syringe with automatic safety device for subcutaneous injection. Label indicates one 1 mL syringe per package. Manufactured for Fresenius Kabi USA, LLC, Lake Zurich, IL. Storage instructions specify 20° to 25°C. Made in India.*

FDA Label Image

Enoxa-label-21.jpg (Enoxa Label 21)

Label for Enoxaparin Sodium Injection, USP, 150 mg per mL, for subcutaneous injection. The label includes the NDC number 63323-589-21 and indicates it is Rx only. Manufactured for Fresenius Kabi USA, LLC, made in India. A QR code is present on the right side of the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.